Ocrelizumab biosimilar (Generium )

N/A

Report date: 2025/08/21 17:58:04

Base Information

Drug NameOcrelizumab biosimilar (Generium )
Drug Alias NameGNR-085
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenerium Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGenerium Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A